As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.
9 Analysts have issued a NextCure, Inc. forecast:
9 Analysts have issued a NextCure, Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -62 -62 |
0%
0%
|
|
| EBIT (Operating Income) EBIT | -63 -63 |
3%
3%
|
|
| Net Profit | -61 -61 |
0%
0%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.
| Head office | United States |
| CEO | Michael Richman |
| Employees | 43 |
| Founded | 2015 |
| Website | www.nextcure.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


